| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Legend Biotech Corporation$27.08
-0.3 (-1.1%)
C 43Pipeline Score Overvalued Pharma · Clinical
Market Cap
5.46 B
EPS
-1.36
P/E Ratio
-
Value Trade
144.62 M
4.45 %
Week
15.9 %
1 Month
60.23 %
3 Month
6.49 %
6 Month
-27.18 %
5 Year
-20.62 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.34 M
52 Week Range
16.24 - 45.30
% held by Insiders
5.11 %
% held by Institutions
49.84 %
Enterprise Value
5.01 B
Total Shares
185.74 M
Short %
7.37 %
Float Shares
176.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Legend Biotech Corporation
394Total events
2Upcoming
90Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 2
Event history 392
Jun 17, 2026
▼Equity OfferingCorporate
Pricing of underwritten public offering of 7,700,000 ADSs at $29.35 per ADS
Jun 15, 2026
▲Late-BreakerLB2501Presentation
Late-breaking presentation of LB2501 proof-of-concept data at EHA 2026
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 15, 2026
▲Topline ReadoutLB2501Clinical Data
Topline data from Phase 1 study of LB2501: 100% ORR and 83.3% CR at DL2
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 15, 2026
▲Primary Endpoint MetLB2501Clinical Data
Primary endpoint of safety met: no DLTs, SAEs, ICANS, or deaths
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 15, 2026
▲Oral PresentationLB2501Presentation
Late-breaking oral presentation at EHA 2026
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 14, 2026
▲Late-BreakerLB2501Presentation
Late-breaking presentation of LB2501 proof-of-concept data at EHA 2026
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 14, 2026
▲Topline ReadoutLB2501Clinical Data
Proof-of-concept data: 100% ORR and 83.3% CR at DL2
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 14, 2026
◆Oral PresentationLB2501Presentation
Oral presentation at EHA 2026 of Phase 1 data for LB2501
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
Jun 1, 2026
◆Poster PresentationCARVYKTIApprovedPresentation
CARTITUDE-4 cytogenetic subgroup analysis of patients responding to bridging therapy
multiple myelomasource ↗
Jun 1, 2026
◆Oral PresentationLB2102Presentation
First-in-human clinical data for LB2102 presented at ASCO 2026
relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC)source ↗
Jun 1, 2026
◆Oral PresentationCARVYKTIApprovedPresentation
Multi-study analysis of IEC-associated enterocolitis presented at ASCO 2026
multiple myelomasource ↗
Drug Pipeline Intelligence
C43
Pipeline Score $2.0B
Pipeline ValueOvervalued
Valuation Signal14
Drugs Scored0.4x
rNPV / MCap Top 62%
Small Cap (rank 347 of 911)
Percentile RankLegend Biotech Corporation carries a moderate pipeline score (43/100), with $3.4B risk-adjusted pipeline value, led by LUCAR-DKS1 NK cells in Relapsed/Refractory Autoimmune Diseases (Phase 1), across $58B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LUCAR-DKS1 NK cells Monoclonal antibody | Relapsed/Refractory Autoimmune Diseases | Phase 1 | NCT07095075 | 35% | $684M | RECRUITING | 36 | STALLED | D (30) | Dec 31, 2029 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LB2501 | relapsed/refractory B-cell non-Hodgkin lymphoma | Phase 1 | 2026-06-15 | objective response rate: 100%; complete response rate: 83.3%; overall response rate: 50.0%; complete response rate overall: 41.7% Read More | Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lympho Read More | |
LB2501 | relapsed/refractory B-cell non-Hodgkin lymphoma | Phase 1 | 2026-06-15 | objective response rate: 100%; complete response rate: 83.3%; overall response rate: 50.0%; complete response rate overall: 41.7% Read More | Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lympho Read More | |
LB2501 | relapsed/refractory B-cell non-Hodgkin lymphoma | Phase 1 | 2026-06-15 | objective response rate: 100%; complete response rate: 83.3%; overall response rate: 50.0%; complete response rate overall: 41.7% Read More | Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lympho Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LEGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LEGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LEGN▼ -16.7%on this news
Legend Biotech Corporation Announces Pricing of Public Offering
Legend Biotech Corporation has announced the pricing of a public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 each, aiming to raise about $226 million. The offering includes an option for underwriters to purchase an additional 1.155 million ADSs. The transaction is set to close on June 23, 2026, pending customary conditions.
Read more →LEGN▼ -16.7%on this newsshared move
Legend Biotech Corporation Announces Proposed Public Offering
Legend Biotech Corporation has announced a proposed public offering of $225 million of American Depositary Shares (ADSs). The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. This move aims to bolster the company's financial resources amidst market uncertainties.
Read more →LEGNLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lympho
Legend Biotech has announced successful early clinical trial results for LB2501, a first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. In a Phase 1 study, the treatment demonstrated a remarkable 100% objective response rate and an 83.3% complete response rate among patients at the higher dose level. The therapy exhibited a favorable safety profile, with no serious adverse events reported. Results were shared at the EHA 2026 Congress, marking a significant step in the advancement of cell therapy.
Read more →LEGNLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech announced positive proof-of-concept results for LB2501, a dual-targeting CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. In a Phase 1 study, LB2501 achieved a 100% objective response rate and an 83.3% complete response rate at the higher dose level. The therapy demonstrated a favorable safety profile with no serious adverse events reported.
Read more →LEGN▲ +42.2%on this news
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Legend Biotech announced promising Phase 1 data for LB2501, a dual-targeting CAR-T therapy for B-cell malignancies. The therapy demonstrated a 100% objective response rate and an 83.3% complete response rate in patients with relapsed/refractory non-Hodgkin lymphoma. The data will be presented at the EHA 2026 Congress, highlighting its potential as a first-in-class treatment.
Read more →LEGN▼ -6.1%on this news· ran to +34% by day 1shared move
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Legend Biotech presented first-in-human results for LB2102, a CAR-T therapy targeting DLL3 in solid tumors, at ASCO 2026. The therapy showed a 28.6% objective response rate and a 78.6% disease control rate among heavily pretreated patients. Additionally, new data on CARVYKTI indicated sustained efficacy and safety in multiple myeloma, reinforcing its role in treatment.
Read more →LEGNLegend Biotech Announces Presentations at ASCO 2026
Legend Biotech announced multiple presentations at the 2026 ASCO Annual Meeting, showcasing preliminary Phase 1 data for LB2102 and new findings from the CARTITUDE-4 study. The rapid oral presentation for LB2102 highlights its potential in treating solid tumors, while additional data on CARVYKTI emphasizes its efficacy in multiple myeloma. The company also plans an investor relations event during the conference.
Read more →LEGN▲ +10.5%on this news
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
Legend Biotech reported a strong performance for Q1 2026, with CARVYKTI sales rising 62% to approximately $597 million. The therapy is now available in 18 global markets, following recent launches. Despite a net loss of $54.3 million, the company maintains a robust cash position of $834.6 million, supporting its growth and development pipeline.
Read more →LEGN▲ +12.3%on this news
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Legend Biotech has engaged a group of distinguished scientific advisors to guide its strategic direction as it advances its cell therapy pipeline. The advisors, who have extensive expertise in oncology and immunology, will contribute insights on emerging science and clinical development. This initiative aims to enhance innovation and expand patient access to next-generation therapies.
Read more →LEGNLegend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Legend Biotech Corporation will hold an investor conference call on May 12, 2026, to discuss its first quarter financial results. The call will include an overview of the company's financial performance by senior management. A live audio webcast will be available, along with a replay and earnings press release on their website.
Read more →LEGNLegend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Legend Biotech reported strong financial results for Q4 and the full year 2025, highlighting CARVYKTI's impressive sales performance with around $1.9 billion in total sales. The company also surpassed the milestone of treating over 10,000 patients with CARVYKTI. Additionally, Legend Biotech showcased advancements in its early-stage cell therapy portfolio and continued expansion of CARVYKTI availability globally. With a solid cash position of approximately $949 million, the company is well-positioned for future growth.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
Legend Biotech Corporation will host an investor conference call on March 10, 2026, to discuss its fourth-quarter and full-year 2025 financial results. Senior management will provide insights into the company's financial performance during the call. A replay and earnings press release will be available on their website shortly after the call.
Read more →LEGN▼ -11.4%on this news
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Legend Biotech will present six poster presentations on CARVYKTI at the 2026 Tandem Meetings, highlighting its efficacy and safety in treating multiple myeloma. The data suggests that earlier administration of CARVYKTI can lead to improved patient outcomes, with significant clinical benefits observed across various trials. However, the therapy is associated with risks, including increased early mortality and severe adverse events.
Read more →LEGNDisclaimer 2 This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant
Legend Biotech Corporation presented details regarding its development track and future prospects, particularly emphasizing its CAR-T therapy, CARVYKTI. The company reported significant clinical achievements, including a high number of patients treated and operational advancements in manufacturing. Financially, Legend anticipates reaching profitability by 2026, supported by robust sales potential of CARVYKTI. However, uncertainties remain around regulatory approvals and safety assessments of investigational therapies.
Read more →LEGNLegend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
Legend Biotech provided positive updates at the 44th Annual J.P. Morgan Healthcare Conference, highlighting that CARVYKTI has surpassed 10,000 patients treated and is expanding its manufacturing capabilities. The company anticipates achieving profitability by 2026, fueled by a robust revenue growth trajectory. New developments in their pipeline, including an investigator-initiated trial for an in vivo candidate and promising preclinical data for dual-targeting CAR-T therapy, showcase the company's commitment to innovation. CEO Ying Huang underscored the strategic priorities for maximizing CARVYKTI's market leadership and expanding global reach.
Read more →LEGNLegend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Legend Biotech Corporation announced that CEO Ying Huang will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will provide the latest updates on the company's advancements in cell therapy, particularly regarding CARVYKTI®, a treatment for multiple myeloma. Investors can access the live webcast through the company's website.
Read more →LEGN▼ -7.1%on this news· ran to -18% by day 3
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Legend Biotech has presented new long-term data for CARVYKTI® at the ASH 2025 meeting, highlighting a median progression-free survival of 50.4 months in heavily pretreated multiple myeloma patients. The findings indicate that earlier treatment correlates with better immune fitness and longer survival. Additionally, first-in-human results for the novel CAR-T candidate LUCAR-G39D in non-Hodgkin lymphoma show promising safety and efficacy profiles.
Read more →LEGN▼ -7.1%on this news· ran to -18% by day 3shared move
Legend Biotech Highlights New CARVYKTI Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
Legend Biotech presented new long-term clinical data on CARVYKTI at ASH 2025, demonstrating a median PFS of 50.4 months for triple-class exposed patients with relapsed/refractory multiple myeloma. The CARTITUDE studies showed that earlier treatment with CARVYKTI leads to better immune fitness and longer PFS. Additionally, early results from the LUCAR-G39D allogeneic CAR-T candidate in non-Hodgkin lymphoma highlighted its manageable safety profile and promising efficacy. However, concerns over early mortality rates and adverse side effects were noted in CARVYKTI patients.
Read more →LEGNLegend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
Legend Biotech has been awarded the Foreign Investor of the Year at the 2025 Flanders International Business Awards, recognizing its significant investment and expansion in Ghent. The company has committed €165 million alongside Johnson & Johnson to enhance its cell therapy manufacturing capabilities. Since starting operations in 2022, Legend Biotech has rapidly grown its workforce in Belgium, reinforcing the region's status as a biotech hub.
Read more →LEGNLegend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Legend Biotech has officially opened a new 31,000-square-foot research and development facility in Philadelphia, enhancing its presence in the U.S. cell therapy sector. The state-of-the-art site will primarily support CAR-T research aimed at oncology and immunology indications. This expansion aligns with the company’s mission to advance innovative therapies and hire approximately 55 full-time employees. Local leaders have welcomed the company's investment, reinforcing Philadelphia's reputation as a significant hub for life sciences.
Read more →LEGNLegend Biotech Reports Third Quarter 2025 Results and Recent Highlights
Legend Biotech reported its third quarter 2025 financial results, highlighting strong revenue growth for CARVYKTI, the leading CAR-T therapy for multiple myeloma. The company anticipates achieving profitability for CARVYKTI by the end of 2025 and overall profitability in 2026. The expansion of their production facility in Belgium is expected to support European market demand.
Read more →LEGNLegend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Legend Biotech announced it will present two oral and seven poster presentations at the 67th ASH Annual Meeting, focusing on CARVYKTI for multiple myeloma and Lucar-G39D for non-Hodgkin lymphoma. The presentations will showcase the durability of responses and evolving safety profiles of CARVYKTI, which is commercially available in 14 countries. The company aims to highlight its innovative cell therapy programs and expand its pipeline.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
Legend Biotech Corporation will hold an investor conference call on November 12, 2025, to discuss its third quarter results. Senior leaders will provide insights into the company's performance during this period. Interested parties can join the live audio webcast, with a replay available shortly after the call. The company continues to lead in cell therapy innovations.
Read more →LEGNLegend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
Legend Biotech Corporation announced its participation in the Morgan Stanley Global Healthcare Conference, where CEO Ying Huang will speak. The event is scheduled for September 9, 2025, and will be accessible via a live webcast. This engagement underscores the company's position as a leader in cell therapy, particularly with its CAR-T product, CARVYKTI.
Read more →LEGNLegend Biotech Appoints Carlos Santos as Chief Financial Officer
Legend Biotech has appointed Carlos Santos as its new Chief Financial Officer, effective immediately. Santos, who has a strong background in finance from his previous roles at AstraZeneca and Intel, will oversee the company's financial operations. His expertise is expected to support the growth of Legend's CAR-T cell therapy franchise and help achieve profitability by 2026.
Read more →LEGNLegend Biotech Reports Second Quarter 2025 Results and Recent Highlights
Legend Biotech reported its second quarter 2025 results, highlighting significant financial and clinical milestones for CARVYKTI. The therapy achieved approximately $439 million in net trade sales and showed positive long-term outcomes, with one-third of patients in the CARTITUDE-1 study remaining progression-free for five years. Additionally, the company announced updates from various studies presented at clinical conferences, with a strong financial position supporting future growth as it aims for profitability in 2026.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
Legend Biotech Corporation is set to host an investor conference call on August 11, 2025, at 8:00 am ET to discuss its second-quarter 2025 results. The call aims to provide insights into the company's performance, which is recognized as a leader in cell therapy. Legend Biotech continues to innovate with its CAR-T therapy, CARVYKTI®, in collaboration with Johnson & Johnson. Investors can access the live audio webcast and an event replay through the company's Investor Relations website.
Read more →LEGN▲ +11.2%on this news
Legend Biotech CORPORATE PRESENTATION JUNE 2025
Legend Biotech's presentation outlines the company's current strategies and performance in developing CARVYKTI, a leading CAR-T therapy for multiple myeloma. They reported a 79% compound annual growth rate (CAGR) since its launch, highlighting its success compared to other CAR-T therapies. The company acknowledges potential risks related to regulatory approvals and market competition. Furthermore, Legend Biotech collaborates with Johnson & Johnson to maximize CARVYKTI's commercial potential.
Read more →LEGNLegend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
Legend Biotech presented long-term survival data for CARVYKTI® at the 2025 ASCO Annual Meeting, revealing that 33% of heavily pretreated multiple myeloma patients remained progression-free for over five years after a single infusion. This data, part of the CARTITUDE-1 study, highlights CARVYKTI's potential to improve treatment outcomes significantly. The findings suggest a paradigm shift in managing relapsed or refractory multiple myeloma, although safety concerns remain.
Read more →LEGNLegend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
Legend Biotech announced new data on CARVYKTI, a CAR-T therapy for multiple myeloma, to be presented at ASCO and EHA. The data includes long-term outcomes from the CARTITUDE-1 study and preliminary results from ongoing Phase 1 studies in solid tumors. The company aims to expand cell therapy's reach into new areas while highlighting the clinical impact of CARVYKTI.
Read more →LEGNLegend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Legend Biotech will host a live webcast for investors during the 2025 ASCO Annual Meeting on June 1, 2025. CEO Ying Huang and CMO Mythili Koneru will present updates on the CARTITUDE development program. This event highlights Legend's commitment to advancing cancer treatment through innovative cell therapies.
Read more →LEGNLegend Biotech Reports First Quarter 2025 Results and Recent Highlights
Legend Biotech reported its first-quarter financial results for 2025, highlighting CARVYKTI® net sales of approximately $369 million and the treatment's positive CHMP opinion for improved survival. The company aims for profitability by next year, driven by manufacturing expansion and market demands, while facing a significant net loss of $100.9 million. Key achievements include over 6,000 patients treated and approvals from TGA in Australia. Despite a dip in license revenue, collaboration revenue saw a substantial increase, affirming the strength of their CAR-T therapies.
Read more →LEGNInternational trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects. We operate in a global economy, and our business
The article discusses the risks posed by international trade policies, tariffs, and sanctions on the company’s financial health and operations. It highlights the reliance on global supply chains and foreign manufacturers, specifically mentioning risks related to U.S.-China trade relations and pharmaceutical tariffs. The company may face increased costs which are difficult to transfer to consumers due to regulatory constraints on drug pricing. The continued uncertainties in global trade may adversely impact the company’s competitive position and ability to access capital markets.
Read more →LEGNLEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT General The board of directors of Legend Biotech Corporation (the Company ) is soliciting proxies for the annual general meeting
Legend Biotech Corporation is soliciting proxies for its annual general meeting of shareholders scheduled for June 12, 2025. Shareholders of record as of May 7, 2025, are entitled to vote on various proposals, including the re-election of directors and the ratification of the independent auditor. The company emphasizes that proper proxy instructions will influence how votes are cast on these proposals. Additionally, the AGM will take place at the company's Somerset, New Jersey offices.
Read more →LEGNLegend Biotech to Host Investor Conference Call on First Quarter 2025 Results
Legend Biotech Corporation will hold an investor conference call on May 13, 2025, at 8:00 am ET to discuss its first-quarter results for 2025. During this call, the company's senior leaders will present an overview of its recent performance. Investors and interested parties can access the live audio webcast through a provided link, with a replay available shortly after the call concludes. Legend Biotech continues to position itself as a pioneer in cell therapy, notably with its CAR-VYKTI® treatment for multiple myeloma.
Read more →LEGN▲ +9.3%on this news
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
Legend Biotech Corporation reported robust financial results for the fourth quarter and full year 2024, highlighting $963 million in total net trade sales from CARVYKTI. The company has treated over 5,000 patients and initiated commercial production at a Novartis facility. Additionally, Spain's national health system approved reimbursement for CARVYKTI, bolstering its market position. With $1.1 billion in cash reserves, the company anticipates a strong financial runway well into 2026.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
Legend Biotech Corporation will conduct an investor conference call on March 11, 2025, to discuss its fourth-quarter and full-year results for 2024. The call is expected to provide insights into the company's performance and future outlook. Interested parties can access the live audio webcast through a provided link, and a replay will be available shortly after the call concludes. Legend Biotech is recognized as a leader in cell therapy, particularly with its treatment for relapsed or refractory multiple myeloma.
Read more →LEGNLegend Biotech CORPORATE PRESENTATION JANUARY 14, 2025
Legend Biotech presented an update on its operations and pipeline on January 14, 2025, highlighting the success of its CAR-T therapy, CARVYKTI, in treating multiple myeloma. The presentation noted significant sales growth, with $286 million in net trade sales recorded in the third quarter of 2024. It emphasized the therapy's superior overall survival outcomes compared to standard treatments, supported by a successful collaboration with Johnson & Johnson. Despite these achievements, the company acknowledged the inherent uncertainties and risks related to drug development and regulatory approvals.
Read more →LEGNDecember 18, 2024 Lori Macomber Re: Transition Agreement Dear Lori: This letter sets forth the substance of the transition agreement (the " Agreement ") which Legend Biotech USA In
Legend Biotech USA Inc. has outlined a transition agreement for Lori Macomber, who has resigned effective January 2, 2025. The agreement ensures she will receive her salary and benefits during a transition period and includes severance benefits such as salary continuation and bonuses. Additionally, the company will cover COBRA premiums for her health insurance for a specified duration and offer outplacement services to assist with her job search. Macomber will continue to vest in her equity awards during this period.
Read more →LEGNLegend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Legend Biotech Corporation announced that its CEO, Ying Huang, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on January 14, 2025, in San Francisco, CA. Investors can access a live audio webcast through Legend's Investor Relations section. Following the presentation, a replay of the webcast will be available approximately 48 hours later.
Read more →LEGNLegend Biotech Reports Third Quarter 2024 Results and Recent Highlights
Legend Biotech reported significant growth in third quarter 2024, with net sales of CARVYKTI reaching approximately $286 million, representing an operational increase of 87.6% year-over-year. The company highlighted CARVYKTI's pivotal role in extending overall survival rates for multiple myeloma patients, supported by positive three-year data from the CARTITUDE-4 study. Expansion efforts include the launch in Switzerland and approval in China, alongside the initiation of commercial production at a new facility in Belgium. However, the company did report a net loss of $125.3 million, up from the previous year.
Read more →LEGNLegend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Legend Biotech Corporation will hold a live investor webcast on December 8, 2024, during the 66th ASH Annual Meeting in San Diego. CEO Ying Huang and CMO Mythili Koneru will present updates on the CARTITUDE development program alongside expert clinicians. The event demonstrates the company's commitment to transparency and engagement with investors as it advances its cell therapy initiatives.
Read more →LEGNLegend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Legend Biotech Corporation will present new data on minimal residual disease (MRD) negativity rates from the CARTITUDE-4 trial at the upcoming ASH Annual Meeting. The study highlights CARVYKTI's potential as a transformative treatment option for refractory multiple myeloma, especially for patients who have already undergone several lines of therapy. Despite the promising outcomes, the presentation will also address significant safety concerns, including higher early mortality rates and the risk of cytokine release syndrome associated with CARVYKTI. The data reinforces the therapeutic value of CARVYKTI against the standard care options available.
Read more →LEGNLegend Biotech Appoints Alan Bash as President of CARVYKTI
Legend Biotech announced the appointment of Alan Bash as the President of CARVYKTI, a crucial role aimed at managing the treatment's growth. This appointment reflects the company's recent successes, including FDA and European Commission approvals for label expansion. Bash has a robust background in oncology and has previously held prominent positions in biopharma, which Legend believes will bolster the CARVYKTI franchise's market position. The company aims to transform multiple myeloma treatment with continued advancements in cell therapy.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
Legend Biotech Corporation will host an investor conference call on November 12, 2024, to discuss its third-quarter 2024 results. Senior leadership will present an overview of the company's performance during this period. Investors can access the call via a live audio webcast, with a recorded replay available shortly after the event. Legend Biotech is focused on developing advanced cell therapies to treat severe diseases.
Read more →LEGNVoting Results of 2024 Annual General Meeting At Legend Biotech Corporation s (the Company ) annual general meeting of shareholders held on
Legend Biotech Corporation held its 2024 Annual General Meeting on October 21, 2024, with 95.3% of outstanding shares represented. Shareholders overwhelmingly supported the reception of the audited financial statements and the appointment of Ernst & Young LLP as independent auditor for the fiscal year. Elections for directors also saw considerable backing, with the majority of candidates receiving over 90% of the votes in favor. The meeting reflected strong shareholder engagement and confidence in the company's governance.
Read more →LEGNLegend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Legend Biotech Corporation announced the establishment of a new state-of-the-art R&D facility in Philadelphia, aimed at advancing its cell therapy portfolio. The facility will add to its global R&D footprint, supporting a growing number of employees and initiatives. This move underscores Legend's commitment to innovation in cell therapies and aims to enhance collaboration with local research institutions. The completion of the facility is anticipated in the third quarter of 2025.
Read more →LEGNLegend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Legend Biotech Corporation will have its CEO, Ying Huang, participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 4, 2024, and is aimed at engaging investors and other interested parties. Following the live event, a webcast replay will be available approximately 48 hours later. This participation highlights Legend Biotech's commitment to advancing cell therapies and its presence in the biotechnology sector.
Read more →LEGNLegend Biotech Reports Second Quarter 2024 Results and Recent Highlights
Legend Biotech reported strong second quarter results for 2024, highlighted by approximately $186 million in net trade sales for CARVYKTI. The drug received approvals from both the MHRA and Health Canada for earlier treatment lines in adult patients with multiple myeloma. Additionally, the second interim analysis of the CARTITUDE-4 study indicated positive overall survival results. The company maintains a robust cash position of $1.3 billion, allowing for potential operational stability through 2026.
Read more →LEGNLegend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
Legend Biotech Corporation has appointed Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors, effective August 9, 2024. Dr. Salovey brings extensive experience in medical research and public health, which is expected to enhance the company's strategic decisions. His appointment reflects Legend's ongoing commitment to leadership excellence as it continues to develop innovative therapies in the CAR-T space and beyond.
Read more →LEGNLegend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
Legend Biotech announced preliminary, unaudited financial results for the six months ended June 30, 2024, revealing an expected adjusted net loss of approximately $94.7 million to $109.7 million. This figure indicates significant financial challenges for the company during this period. The company plans to release full auditing results on August 9, 2024. Current estimates are subject to change and do not replace fully audited financial statements.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
Legend Biotech will hold a conference call on August 9, 2024, to discuss its second-quarter 2024 results. Senior leaders are expected to provide a comprehensive overview of the company's performance during this period. The call will be accessible to investors through a webcast, and a replay will be available shortly after the conclusion. This event demonstrates Legend Biotech's commitment to investor relations and transparency in reporting results.
Read more →LEGNLegend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
Legend Biotech announced positive overall survival results from the CARTITUDE-4 Phase 3 trial, showing that CARVYKTI significantly benefits adult patients with relapsed and lenalidomide-refractory multiple myeloma. The results from the interim analysis indicated a meaningful improvement in overall survival without new safety signals identified. However, a higher percentage of early deaths and the occurrence of Cytokine Release Syndrome and neurologic toxicities were noted, raising safety concerns. These findings will be presented at a medical meeting and will be shared with regulatory agencies for label updates.
Read more →LEGNLegend Biotech Corporate Presentation This presentation is for investor relations purposes only - Not for product promotional purposes JANUARY 2024 Disclaimer 3 This presentation is for investor relations purposes only -
Legend Biotech recently presented an investor relations update highlighting the continued growth of its CAR-T therapy, CARVYKTI, which has demonstrated impressive sales increases in both U.S. and EU markets. The company's manufacturing capacity is expanding with sites in the U.S., EU, and China, aiming to meet increasing demand. Future expectations include a sBLA application accepted by the U.S. FDA and EMA for label expansion, with a target action date set for April 2024. Legend Biotech's pipeline also features several promising programs targeting various malignancies.
Read more →LEGNPatient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI (ciltacabtage
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI (ciltacabtagene autoleucel) In CARTITUDE-4, CARVYKTI demonstrated clinica
Read more →LEGNLegend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3 The deal with Novartis seeks to advance Legend Biotech's autologous CAR-T cell therapy candidate, LB2102, and other
Legend Biotech has announced a global license agreement with Novartis to develop CAR-T therapies targeting DLL3, notably the candidate LB2102. Legend will receive a $100 million upfront payment, with potential for additional milestone payments. The agreement allows Novartis to utilize its T-Charge platform for CAR-T cell therapy manufacturing. LB2102 is being developed for small cell lung cancer following FDA clearance and Orphan Drug Designation. The deal remains contingent on necessary regulatory approvals.
Read more →LEGNVoting Results of 2023 Annual General Meeting At Legend Biotech Corporation s (the Company ) annual general meeting of shareholders held on
Legend Biotech Corporation held its 2023 Annual General Meeting on September 21, 2023, where shareholders voted on several key resolutions. A significant portion, approximately 99.34%, of the ordinary shares were represented at the meeting. The shareholders overwhelmingly supported the audited financial statements and the appointment of Ernst & Young LLP as independent auditor for the fiscal year. Additionally, directors were elected with substantial majority vote margins, reflecting strong shareholder confidence in the company's leadership.
Read more →LEGNLegend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI (ciltacabtagene autoleucel) The application is supported by the Phase 3 CARTITUDE-4 study, which showed signifi
Legend Biotech has submitted a supplemental Biologics License Application (sBLA) to the FDA to seek expanded use of CARVYKTI for treating adult patients with relapsed and lenalidomide-refractory multiple myeloma. This application is backed by the Phase 3 CARTITUDE-4 study, demonstrating significant improvements in progression-free survival against standard regimens. CARVYKTI is a BCMA-directed immunotherapy, but it carries risks including serious side effects such as Cytokine Release Syndrome and neurological toxicities. The submission reflects Legend's commitment to increasing treatment options for multiple myeloma patients.
Read more →LEGNCiltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study First analysis data fro
The Phase 3 CARTITUDE-4 study results revealed that ciltacabtagene autoleucel (cilta-cel) significantly reduces the risk of disease progression or death by 74% compared to standard regimens in adult patients with relapsed and refractory multiple myeloma. This study is notable for its randomized approach in assessing cell therapy against conventional treatments. At a median follow-up of 16 months, cilta-cel demonstrated impressive overall response rates and prolonged progression-free survival. However, the treatment was associated with high rates of grade 3 or 4 adverse events, raising safety concerns.
Read more →LEGNLegend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI (ciltacabtagene autoleucel) The application to the European Medicines Agency is supported by data from the Phase 3 CARTITU
Legend Biotech has submitted a Type II variation application to the European Medicines Agency (EMA) for the expanded use of CARVYKTI, a CAR T-cell therapy targeting multiple myeloma. This application is based on data from the Phase 3 CARTITUDE-4 study, which assesses the therapy's efficacy in patients with relapsed and lenalidomide-refractory multiple myeloma. Results from this study are expected to be presented at the upcoming ASCO and EHA meetings. While the therapy shows promise, it carries significant risks, including severe adverse reactions.
Read more →LEGNLegend Biotech Reports First Quarter 2023 Results and Recent Highlights New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be pre
Legend Biotech reported its first-quarter 2023 financial results, showing a significant net loss of $112.1 million. The company raised $762 million in funding to support its growth and appointed new key personnel, including a Chief Medical Officer and strategic advisors. The first quarter also saw a decline in total revenue compared to the previous year, primarily attributed to changes in collaboration revenue related to CARVYKTI sales. Looking forward, Legend Biotech plans to present updated clinical data at upcoming major conferences in June.
Read more →LEGNLegend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continu
Legend Biotech announced its participation in the 2023 ASCO and EHA Annual Meetings, where it will showcase new data from its CARTITUDE Clinical Development Program. Notably, the first analysis from the Phase 3 CARTITUDE-4 study will be presented, highlighting the treatment of relapsed multiple myeloma patients using cilta-cel versus standard-of-care therapies. In addition, long-term safety and efficacy results from the Legend-2 trial will also be discussed. This presentation reflects Legend's ongoing commitment to advancing treatments for patients with multiple myeloma and demonstrates their leadership in CAR-T cell therapy research.
Read more →LEGNLegend Biotech Corporation Announces Pricing of Registered Direct Offering of US$350 million of American Depositary Shares SOMERSET, NJ
Legend Biotech Corporation announced the pricing of a registered direct offering of American Depositary Shares (ADSs) amounting to $350 million. The offering will consist of 5,468,750 ADSs priced at $64.00 each and is expected to close around May 10, 2023. Proceeds from this offering will help fund the company's operating expenses and capital needs through the fourth quarter of 2025. The offering is subject to customary closing conditions and follows an effective shelf registration statement with the SEC.
Read more →LEGN▲ +9.3%on this news
Background: CARTITUDE-4 is a global, phase 3, randomized, controlled trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel), a dual-binding, B-cell maturation antigen-targeting chimeric antigen receptor (CAR)-T cel
CARTITUDE-4 is a phase 3 trial evaluating ciltacabtagene autoleucel (cilta-cel) against standard of care in lenalidomide-refractory patients. The trial met its primary endpoint, showing a 74% reduction in the risk of progression or death for the cilta-cel group compared to the SOC group, along with higher overall response rates. However, significant adverse events, including cytokine release syndrome and patient mortality, were reported in both treatment groups. The findings suggest cilta-cel may offer a promising option for multiple myeloma after first relapse.
Read more →LEGNCertain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. MASTER TECHNOLOGY TRANSFER, MANUFACTURING AND
Legend Biotech USA Inc. and Janssen Research & Development have entered into a Master Technology Transfer, Manufacturing, and Clinical Supply Services Agreement for a BCMA CAR-T product. The agreement involves collaboration with Novartis Pharmaceuticals and outlines responsibilities regarding data management, product supply, and operational execution. It emphasizes regulatory compliance, data protection, and the potential for continued partnerships in cell and gene therapy. This formal agreement marks a significant step in advancing their shared clinical goals in oncology.
Read more →LEGNLegend Biotech Establishes Strategic Advisory Board SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech has established a strategic advisory board to guide its initiatives. The board includes notable figures such as Michel Vounatsos, former CEO of Biogen, and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals. Their extensive expertise is expected to be pivotal in advancing Legend Biotech's cell therapy platforms. CEO Ying Huang expressed enthusiasm about the new advisors' capabilities and perspectives contributing to the company's long-term growth.
Read more →LEGNLegend Biotech Reports Full-Year 2022 Results and Recent Highlights CARTITUDE-4, a Phase 3 study of CARVYKTI (ciltacabtagene autoleucel) meets primary endpoint at the study's first pre-specified interim analysis FDA clea
Legend Biotech reported its full-year 2022 results showcasing significant milestones, including the successful interim analysis of the CARTITUDE-4 study, which met its primary endpoint. The company received regulatory approvals for CARVYKTI in the U.S., Europe, and Japan, as well as FDA clearance for LB2102 in small cell lung cancer. Despite a significant revenue increase to $117 million, the company reported a net loss of $446.3 million. Legend also highlighted ongoing investments in pipeline expansion and operational infrastructure.
Read more →LEGNLegend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma SOMERSET, N.J.--(BUSINESS
Legend Biotech announced the successful results from the Phase 3 CARTITUDE-4 study of CARVYKTI (ciltacabtagene autoleucel) for treating relapsed and refractory multiple myeloma. The study met its primary endpoint of significantly improving progression-free survival when compared to standard therapies at the first interim analysis. This international study will inform future regulatory submissions and aims to expand treatment options for patients with challenging medical histories. Results will also be presented at an upcoming medical meeting.
Read more →LEGN▼ -6%on this news
Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech received a notification from Nasdaq indicating non-compliance with listing rules due to a failure to submit required financial documents. The company missed the deadline to file an interim balance sheet and income statement for the quarter ended June 30, 2022. Legend Biotech has been working on a restatement of its financial statements from previous years, which caused the delay. The company has a 60-day period to propose measures to regain compliance, with the possibility of an extension of up to 180 days if accepted.
Read more →LEGNLegend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech announced that its New Drug Application for ciltacabtagene autoleucel (cilta-cel) has been accepted by China's National Medical Products Administration. This marks a significant step in bringing the therapy for relapsed or refractory multiple myeloma to the Chinese market, following data from a confirmatory Phase 2 study, CARTIFAN-1. The demand for effective treatment remains high due to increasing incidence and mortality rates of multiple myeloma in China. Cilta-cel is already approved in other regions, including the U.S. and Europe.
Read more →LEGNPreclinical Phase 1 GASTRIC, ESOPHAGEAL & PANCREATICt (CLAUDIN 18.2) Auto logous NCT04467853 RRMM (BCMA) LEGEND-2t Auto logous NCT03090659 IGlobal IUS I China Phase 2 MMt (BCMA) Al logeneic - CAR-NK NCT05498545 MMt (BCMA
Preclinical Phase 1 GASTRIC, ESOPHAGEAL & PANCREATICt (CLAUDIN 18.2) Auto logous NCT04467853 RRMM (BCMA) LEGEND-2t Auto logous NCT03090659 IGlobal IUS I China Phase 2 MMt (BCMA) Al logeneic - CAR-NK NCT05498545 MMt (BCMA) A llogeneic - CAR-yo T NCT05376345 NHLt /ALLt (CD19 X CD2
Read more →LEGNLegend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer SOMERSET, N.J.--(BUSINESS WIRE)--November 21, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing
Read more →LEGNLegend Biotech Announces Participation in Upcoming Investor Conferences SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces Participation in Upcoming Investor Conferences SOMERSET, N.J.--(BUSINESS WIRE)--November 4, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to
Read more →LEGNLegend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022 Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients w
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022 Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients with multiple myeloma New analysis of sustained minimal res
Read more →LEGNVoting Results of 2022 Annual General Meeting At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on
Voting Results of 2022 Annual General Meeting At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on October 14, 2022 (the "AGM"), the Company's shareholders: A total of approximately 324,090,586 ordinary shares, including those underlyin
Read more →LEGNCARVYKTI (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma SOMERSET, N.J.--(BUSINESS WIRE)
CARVYKTI (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma SOMERSET, N.J.--(BUSINESS WIRE)--September 27, 2022--Legend Biotech Corporation (NASDAQ: L
Read more →LEGNLEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 PROXY STATEMENT General The board of directors of Legend Biotech Corporation (the " Company ") is soliciting proxies for the annual general meeti
LEGEND BIOTECH CORPORATION 2101 Cottontail Lane Somerset, New Jersey 08873 The board of directors of Legend Biotech Corporation (the "Company") is soliciting proxies for the annual general meeting of shareholders of the Company to be held on October 14, 2022 at 9:30 a.m. (loca
Read more →LEGNLegend Biotech to Host 2022 R&D Day on Monday
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022 SOMERSET, N.J.--(BUSINESS WIRE)--September 15, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat l
Read more →LEGNLegend Biotech Announces Preliminary Results for the Six-Months Ended
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022 SOMERSET, N.J.--(BUSINESS WIRE)--August 5, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel th
Read more →LEGNLegend Biotech Appoints Three New Directors and Elects New Chairman of the Board SOMERSET, N.J. (BUSINESS WIRE)
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board SOMERSET, N.J. (BUSINESS WIRE) August 4, 2022 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapi
Read more →LEGN▼ -13.9%on this news
Legend Biotech Corporation Announces Pricing of Public Offering SOMERSET, NJ
Legend Biotech Corporation Announces Pricing of Public Offering SOMERSET, NJ July 26, 2022 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening disea
Read more →LEGNLegend Biotech Corporation Announces Proposed Public Offering SOMERSET, NJ
Legend Biotech Corporation Announces Proposed Public Offering SOMERSET, NJ July 25, 2022 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases
Read more →LEGNCertain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO INTERIM PRODUCT SUPPLY AGR
[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO INTERIM PRODUCT SUPPLY AGREEMENT This Amendment No. 1 to the Interim Product
Read more →LEGNLonger-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma 28-month, median follow-up data from the CARTIT
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma 28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refra
Read more →LEGN▲ +6.4%on this newsshared move
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers SOMERSET, N.J.--(BUSINESS WIRE)--June 3, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global
Read more →LEGNLegend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights The U.S. Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with rela
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights The U.S. Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma, marking Legend Biotech
Read more →LEGNLegend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting SOMERSET, N.J.--(BUSINESS WIRE)--May 31, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commer
Read more →LEGNCARVYKTI (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma C ARVYKTI is Legend Biotech's first European Commis
CARVYKTI (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma CARVYKTI is Legend Biotech's first European Commission-approved product The approval is based on the pivotal
Read more →LEGNLegend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA Longer term follow-up data will be presented from the pivotal CARTITUDE-1
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple mye
Read more →LEGN▼ -7.1%on this news
Legend Biotech Appoints Lori Macomber as Chief Financial Officer SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Appoints Lori Macomber as Chief Financial Officer SOMERSET, N.J.--(BUSINESS WIRE)--May 9, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-t
Read more →LEGNLegend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T SOMERSET, N.J.--(BUSINESS WIRE)--April 21, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and com
Read more →LEGN▲ +7.6%on this news
Legend Biotech Announces Appointment of Global Head of Research and Early Development SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces Appointment of Global Head of Research and Early Development SOMERSET, N.J.--(BUSINESS WIRE)--April 1, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel th
Read more →LEGN▼ -5.1%on this news
CARVYKTI (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Ciltacabtagene autoleucel, if approved by the European Commission (EC), will
CARVYKTI (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Ciltacabtagene autoleucel, if approved by the European Commission (EC), will be Legend Biotech's first EC-approved product SOMERSET, N
Read more →LEGNLegend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights U.S. Food Drug Administration approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel), a BCMA-directed CAR T-cell therapy
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights U.S. Food Drug Administration approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel), a BCMA-directed CAR T-cell therapy for the treatment of adults with relapsed or refractory mul
Read more →LEGNCARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma CARVYKTI marks the first product approved by
CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma CARVYKTI marks the first product approved by a health authority for Legend Biotech Approval is primaril
Read more →LEGNLegend Biotech Announces Preliminary Results for the Year Ended
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021 SOMERSET, N.J.--(BUSINESS WIRE)--February 18, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel the
Read more →LEGNLegend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901 SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901 SOMERSET, N.J.--(BUSINESS WIRE)--February 15, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel t
Read more →LEGNLegend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen SOMERSET, N.J.--(BUSINESS WIRE)--February 11, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel t
Read more →LEGNLegend Biotech to Participate in the 40 th Annual J.P. Morgan Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech to Participate in the 40 th Annual J.P. Morgan Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)--January 4, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel the
Read more →LEGN▲ +5.3%on this newsshared move
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors SOMERSET, N.J.--(BUSINESS WIRE)--December 30, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global, clinical-stage biotechnology company developing and manufacturing novel th
Read more →LEGNTwo-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma Updated CARTITUDE-1 data presented at ASH 2021 d
Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma Updated CARTITUDE-1 data presented at ASH 2021 demonstrate a 98 percent overall response rate and 83 percen
Read more →LEGN▲ +9.8%on this news
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63 rd American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63 rd American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J.--(BUSINESS WIRE)--December 7, 2021--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnolo
Read more →LEGNLegend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen Submission based on da
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen Submission based on data from pivotal CARTITUDE-1 trial SOMERSET, N.J.--(BUSINES
Read more →LEGN▲ +7.3%on this news
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights Enrollment of the Phase 3 CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) for multiple myeloma patients with 1-3 prior
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights Enrollment of the Phase 3 CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) for multiple myeloma patients with 1-3 prior lines of therapy was completed by Janssen Biotech, Inc. U.
Read more →LEGN▼ -5.8%on this news
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH Updated data from the pivotal CARTITUDE-1 study of cilta-ce
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH Updated data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated adults with multiple myeloma will b
Read more →LEGNLegend Biotech Announces Extension of PDUFA Date for Cilta-Cel SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel SOMERSET, N.J.--(BUSINESS WIRE)--November 1, 2021--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announ
Read more →LEGNLegend Biotech to Host R&D Day on
Legend Biotech to Host R&D Day on October 18, 2021 SOMERSET, N.J.--(BUSINESS WIRE)--September 22, 2021--Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and
Read more →LEGNLegend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma SOMERSET, N.J.--(BUSINESS WIRE)--September 13, 2021--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical
Read more →LEGNLegend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)--August 30, 2021--Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of
Read more →LEGN▲ +6.5%on this news
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights Investigational BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel) granted priority review by the U.S. Food and Drug Administration
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights Investigational BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel) granted priority review by the U.S. Food and Drug Administration for the treatment of relapsed or refractory multiple myelo
Read more →LEGNLegend Biotech Announces Advancement of Global Manufacturing Infrastructure New Cell Therapy Facility in Belgium Establishes Manufacturing Presence in the European Union New facility builds upon Legend Biotech's collabor
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure New Cell Therapy Facility in Belgium Establishes Manufacturing Presence in the European Union New facility builds upon Legend Biotech's collaboration with Janssen to advance the manufacturing of investi
Read more →LEGNVoting Results of 2021 Annual General Meeting At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on
Voting Results of 2021 Annual General Meeting At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on June 9, 2021 (the "AGM"), the Company's shareholders: A total of approximately 247,197,098 ordinary shares, including those underlying AD
Read more →LEGNJune 2021 Disclaimer This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Comp
Disclaimer This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.The safety and efficacy of the agents and/or uses under investiga
Read more →LEGNLegend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings Longer-term re
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings Longer-term results from the Phase 1b/2 CARTITUDE-1 study demonstrated 98
Read more →LEGNU.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma SOMERSET, N.J. (BUSINESS WIRE)
U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma SOMERSET, N.J. (BUSINESS WIRE) May 26, 2021 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceut
Read more →LEGNLegend Biotech to Present at the Jefferies Virtual Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference SOMERSET, N.J.--(BUSINESS WIRE)--May 25, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov
Read more →LEGNLegend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights Rolling submission of BLA to the FDA completed for ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed or refractory multi
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights Rolling submission of BLA to the FDA completed for ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) European Marketing Authorisation Appli
Read more →LEGNLegend Biotech Reports Compelling New and Updated Data from BCMA CAR-T Program at Upcoming 2021 ASCO and EHA Meetings Longer term follow-up data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated patie
Legend Biotech Reports Compelling New and Updated Data from BCMA CAR-T Program at Upcoming 2021 ASCO and EHA Meetings Longer term follow-up data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated patients with relapsed or refractory multiple myeloma The fir
Read more →LEGNforward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma Submission follows accelerated assessment granted by the Committee f
Read more →LEGNLegend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a succe
Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 mi
Read more →LEGNLegend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call SOMERSET, N.J.--(BUSINESS WIRE)--March 10, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and devel
Read more →LEGNLegend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma SOMERSET, N.J.--(BUSINESS WIRE)
Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma SOMERSET, N.J.--(BUSINESS WIRE)--February 1, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a
Read more →LEGNDisclaimer This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.The sa
Disclaimer This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.The safety and efficacy of the agents and/or uses under investiga
Read more →LEGNLegend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma Leg
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma Legend Biotech also achieves fifth milestone payment under it
Read more →LEGNLegend Biotech Added to the NASDAQ Biotechnology Index SOMERSET, N.J.
Legend Biotech Added to the NASDAQ Biotechnology Index SOMERSET, N.J., December 14, 2020 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology
Read more →LEGNLegend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma SOMERSET, N.J.
Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma SOMERSET, N.J., December 14, 2020 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global clinical-stage
Read more →LEGNLegend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma Combined Phase 1b/2 CARTITUDE-1
Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma Combined Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 Annual Meeting show 97 percent
Read more →LEGNLegend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors SOMERSET, N.J.
Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors SOMERSET, N.J., December 3, 2020 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel
Read more →LEGNLegend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62 nd American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J.
Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J., November 24, 2020 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host
Read more →LEGNLegend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang Zhang SOMERSET, N.J.
Legend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang Zhang SOMERSET, N.J., November 23, 2020 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global clinical-stage biopharmaceutical company engaged in the discovery
Read more →LEGNLegend Biotech Reports Third Quarter 2020 Financial Results SOMERSET, N.J. (BUSINESS WIRE)
Legend Biotech Reports Third Quarter 2020 Financial Results SOMERSET, N.J. (BUSINESS WIRE) November 16, 2020 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech or the Company ), a global clinical-stage biopharmaceutical company engaged in the discovery and development o
Read more →LEGNLegend Biotech Announces Leadership Transition Ye (Sally) Wang Appointed Chairwoman of the Board Ying Huang Named
Legend Biotech Announces Leadership Transition Ye (Sally) Wang Appointed Chairwoman of the Board Ying Huang Named CEO N.J., November 9, 2020 Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global clinical-stage biopharmaceutical company engaged in the discovery
Read more →LEGNLegend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRM
Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA in Development for Patients with Relapsed and/or Refractory Multiple SOMERSET, N.J., November 5, 2020 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biote
Read more →LEGNLEGEND BIOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Legend Biotech Corporation on Behalf of Legend Biotech Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Legend Biotech Corporation (NASDAQ: LEGN) on behalf of Legend Biotech stockholders. Our investigation concerns w
Read more →LEGNLegend Biotech Corporation Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 25, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN) investors that the firm has initiated an i
Read more →LEGNLegend Biotech Names Current Chief Financial Officer, Ying Huang, as Interim CEO
Legend Biotech Names Current Chief Financial Officer, Ying Huang, as Interim CEO September 21, 2020 SOMERSET, N.J. Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel
Read more →LEGNLegend Biotech Reports Second Quarter 2020 Financial Results SOMERSET, N.J. (BUSINESS WIRE)
Legend Biotech Reports Second Quarter 2020 Financial Results SOMERSET, N.J. (BUSINESS WIRE) August 28, 2020 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell thera
Read more →LEGNThe China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CA
The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy First investigational product being recom
Read more →LEGNLegend Biotech Announces Preliminary Results for First Half of 2020
Legend Biotech Announces Preliminary Results for First Half of 2020 SOMERSET, N.J. (BUSINESS WIRE) Legend Biotech (NASDAQ: LEGN) today announced preliminary results for the first half of 2020. For the six months ended June 30, 2020, Legend Biotech expects to record a loss fro
Read more →LEGNLegend Biotech Announces Chief Executive Officer Transition SOMERSET, N.J. (BUSINESS WIRE)
Legend Biotech Announces Chief Executive Officer Transition SOMERSET, N.J. (BUSINESS WIRE) August 2, 2020 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapi
Read more →Competitive Position
How LEGN ranks across every disease it competes inCompetitive Position is a premium feature
See how LEGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial